We are excited to meet with you in the ASH virtual space and to introduce you to AVM Biotechnology and AVM0703. An invitation from our Founder and CSO:

AVM0703 triggers the production and release of endogenous bispecific gamma delta+ Natural Killer T-cells (AVM-NKT). These naturally occurring supercharged immune cells have unique properties and appear rapidly in the blood following a single dose of AVM0703. Preclinical data indicate that AVM0703 potentiates chemotherapy. It also has activity in solid tumors and autoimmune disorders.

Advantages of AVM0703

• Durable Clinical Response in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)/Leukemia including T-cell Lymphoma – 28-day response
• No Dose Limiting Toxicities (DLT’s) or Adverse Events of Special Interest (AESI’s) reported in the clinical trial and solid-tumor compassionate use cases
• Rapidly induces, expands, and mobilizes endogenous bispecific gamma delta invariant TCR by a glucocorticoid-receptor-independent mechanism
• Well-established clinical development pathway for expeditious FDA approval
• Potentiates chemotherapy and Car-T response in pre-clinical models

AVM Biotechnology Is:

• Actively enrolling patients in the clinical trial (NCT04329728: The WWRD Study: AVM0703 for Treatment of Leukemia or lymphoma)
• Accepting new trial sites for the efficacy phase set to begin in early 2022
• Seeking a partner for commercial launch targeted in 2023

Recent ASH Publications